

### Amendments to the Claims

1. (Currently amended) A peptide ~~Peptides characterized comprising a compound having~~ in the general structural formula:



or pharmaceutically acceptable salts, or ethers, or amides thereof,  
wherein  $X_1$  is absent or comprises no less than 1 amino acid, and  
 $X_2$  is absent or comprises no less than 1 amino acid.

2. (Currently amended) The peptide of claim 1, comprising up to 30 amino acid residues, ~~preferably 5-15 amino acid residues.~~

3. (Original) The peptide of claim 1, wherein  $X_1$  is selected from the group consisting of 0 amino acid, His-Gly-Val-Ser-Gly-, His-Gly-Gly-Gly-, His-Val-Gly-Gly-, His-Gly-Gly-Gly-Gly, Gln-Gly-Gly-Gly-Gly and His-Gly-Gly-Gly-.

4. (Original) The peptide of claim 1, wherein  $X_2$  is selected from the group consisting of 0 amino acid, -His-Gly-Thr-His-Gly-, -Gly-Gly-Thr-His-Gly-, -Pro-His-Val-Gly-Gly-, -Pro-His-Gly-Gly-Gly-, -Pro-His-Gly-Gly-Gly-Trp-Gly-, -Gly-Gly-Gly-Thr-His-Ser.

5. (Currently amended) The peptide of claim 1 selected from the group consisting of His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID NO 1), His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly (SEQ NO 2), His-Gly-Gly-Gly-Gly-Trp-Gly-Gln-Gly-Gly-Thr-His-Gly (SEQ ID NO 3), His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Val-Gly-Gly (SEQ ID NO 4), His-Val-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly (SEQ NO 5), Gln-Gly-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly (SEQ ID NO 9), His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly (SEQ ID NO 10), and His-Gly-Gly-Gly-Trp-Gly-Gln-His-Gly-Gly-Gly-Trp-Gly (SEQ ID NO 11).

6. (Currently amended) A protein ~~Proteins and polypeptides~~ comprising the amino acid sequences of claim 1.

7. (Currently amended) The peptides of claim 1, having antiproliferative and cytotoxic activity.

8. (Currently amended) The peptides of claim 1, having antitumoral activity.

9. (Currently amended) The peptides of claim 1, having antiviral activity.

10. (Currently amended) The peptides of claim 1, having immunomodulating activity.

11. (Currently amended) The proteins and ~~polypeptides~~ of claim 6, having antitumoral activity.

12. (Currently amended) The proteins and ~~polypeptides~~ of claim 6, having antiviral activity.

13. (Currently amended) The proteins and ~~polypeptides~~ of claim 6, having immunomodulatory activity.

14. (Currently amended) A chemical ~~Chemical~~ compounds ~~being not natural peptides or proteins~~, having anti-proliferative, cytotoxic, antitumoral or antiviral activity, comprising the aminoacid sequence as defined in claim 1, wherein the chemical compound is not a natural peptide or protein.

15. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ compositions including comprising the peptides of claim 1.

16. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ compositions including comprising the proteins and ~~polipeptides~~ of claim 4 6.

17. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ compositions including comprising the chemical compounds of claim 14.

18. (Original) A nucleotide sequence coding any one of the peptides of claim 1.

19. (Currently amended) A vector suitable for the expression of ~~any one of the~~ peptides of claim 1 in a host cell which expresses said peptide after transformation, ~~including a DNA fragment coding the peptide of any of claim 1.~~

20. (Currently amended) A host cell transformed by the vector of claim 20 19.

21. (New) The peptide of claim 1, comprising 5 to 15 aminoacid residues.

22. (New) A polypeptide comprising the aminoacid sequence of claim 1.

23. (New) The polypeptide of claim 22, having antitumoral activity.

24. (New) The polypeptide of claim 22, having antiviral activity.

25. (New) The polypeptide of claim 22 , having immunomodulatory activity.

26. (New) A pharmaceutical composition comprising the polypeptide of claim 22.